Merck’s Keytruda is also being studied in numerous vaccine combination trials, including in prostate cancer, bladder cancer, colorectal and pancreatic cancer. One of the agents being studied in ...

In an interview with pharmaphorum, Goodfellow said the backing of CRUK was an endorsement of Scancell and its cancer vaccine platform. After years of failures (most notably prostate cancer vaccine ...

Data from a clinical study of DNA-based prostrate cancer demonstrated that Inovio’s DNA delivery technology enhanced the potency of the gene-based vaccine. The study shows that human embryonic stem ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Men who avoided prostate cancer screening appointments were significantly more likely to die from the disease, according to ...

Dublin, March 25, 2025 (GLOBE NEWSWIRE) -- The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...